

Full Paper

## Synthesis of (*R*)-Dihydropyridones as Key Intermediates for an Efficient Access to Piperidine Alkaloids

Evangelia N. Tzanetou <sup>1</sup>, Konstantinos M. Kasiotis <sup>1</sup>, Prokopios Magiatis <sup>2</sup> and Serkos A. Haroutounian <sup>1,\*</sup>

<sup>1</sup> Chemistry Laboratory, Agricultural University of Athens, Iera odos 75, Athens 11855, Greece

<sup>2</sup> Faculty of Pharmacy, Laboratory of Pharmacognosy and Natural Products Chemistry, University of Athens, Panepistimiopolis Zografou, Athens 15771, Greece

\* Author to whom correspondence should be addressed; E-mail: sehar@aua.gr

Received: 13 March 2007; in revised form: 25 March 2007 / Accepted: 27 March 2007 /

Published: 10 April 2007

---

**Abstract:** The efficient transformation of *D*-glucal to (2*R*)-hydroxymethyldihydropyridinone **5** in seven steps and 35 % overall yield is reported. Dihydropyridone **5** constitutes a versatile chiral building block for the synthesis of various piperidine alkaloids. In this regard, **5** was converted to piperidinol **13** and piperidinone **15**, that may be further elaborated for the syntheses of (+)-desoxoprosophylline (**1**) and deoxymannojirimycin (**3**) or *D*-mannolactam (**4**), respectively.

**Keywords:** Dihydropyridones, piperidine alkaloids, azasugars, asymmetric synthesis


---

### Introduction

Piperidine alkaloids comprise a large family of compounds that exhibit a large spectrum of biological activities of medicinal interest. In particular, alkaloid lipids such as (+)-desoxoprosophylline (**1**, Figure 1) [1] display significant anesthetic, analgesic and antibiotic activities [2-4], while their corresponding iminosugars – exemplified by N-butyl-1-deoxynojirimycin (NB-DNJ, **2**) which was recently approved for the treatment of Gaucher disease [5] – constitute promising leads for the development of immunosuppressive [6], antiviral [7], antidiabetic [8] and antitumour agents [9]. In

addition, deoxymannojirimycin (**3**) and D-mannolactam (**4**, Figure 1) have also shown to inhibit various enzymes that participate in the binding and processing of diverse glycoproteins, underlying their possible therapeutic values [10–12].

**Figure 1.** Piperidine Alkaloids and Key Intermediate Dihydropyridone **5**.



As a result intense research efforts have been devoted to the development of methodologies and synthetic strategies for the efficient preparation of these compounds and derivatives. Most of these methods utilize sugars or amino acids as their chiral pool synthons [13–19] and suffer from a lack of selectivity and applicability to diverse compounds. On the other hand, the optically active 1,6-dihydro-2*H*-pyridin-3-ones represent flexible building blocks for the efficient access to diverse multifunctionalized bioactive indolizines, quinolizidines and piperidine alkaloids [20]. Recently, we reported the preparation of (2*S*)-hydroxymethyldihydropyridinone, [21] a chiral key intermediate for the synthesis of various piperidine alkaloids such as (–)-desoxoprosophylline, allonojirimycin and indolizidine alkaloids (e.g. swainsonine). The common structural feature of all the aforementioned molecules is the (*S*)-configuration at C–2. Herein we present an efficient and highly enantioselective route to its (*R*)-enantiomer **5** starting from the commercially available *D*-glucal. This molecule represents a key intermediate for the synthesis of broad variety natural and unnatural piperidine alkaloids and/or iminosugars displaying an (*R*)-configuration at C–2.


## Results and Discussion

The key step for the implementation of the proposed synthetic sequence is the synthesis of chiral (*R*)-*N*-[2-(*tert*-butyldiphenylsilyloxy)-1-furan-2-yl-ethyl]-4-methylbenzenesulfonamide (**10**), since all final products retain that stereochemistry. Commercially available *D*-glucal was used as starting material for the synthesis of this intermediate. More specifically, *D*-glucal was reacted with HgSO<sub>4</sub> (as a solution in 0.002 M H<sub>2</sub>SO<sub>4</sub>) and subsequently its primary hydroxy group was protected with TBDPSCl to provide the 2-furyl glycol (+)-**6**, according to a literature procedure reported by Hauser *et al.* (Scheme 1) [22].

The stereochemistry of compound **6** was efficiently inverted using the Mitsunobu protocol (DEAD,  $\text{Ph}_3\text{P}$ , benzoic acid) affording the (*S*)-ethyl-2-(*tert*-butyldiphenylsilyloxy)-1-furan-2-yl-benzoate **7**, which was further saponified to afford (*S*)-1-furan-2-yl-ethanol **8**. The displacement of the secondary hydroxy group with azide with inversion of configuration was performed in high enantiomeric excess (>98%) on treating **8** with DBU in toluene and DPPA. The enantiomeric excess was determined by hydrogenating compound **9** over 10% Pd/C (4 mg) under 1 bar pressure for 40 min [23]. The mixture was filtered over Celite<sup>®</sup> and the amine was then derivatized by adding  $\text{Et}_3\text{N}$  and (–)-menthyl chloroformate. The ratio of enantiomers was determined by reversed-phase HPLC [Kromasil 100-5, C-18,  $\text{H}_2\text{O}/\text{MeOH}/\text{CH}_3\text{CN}$  gradient elution from 40:40:20 to 0:10:90, flow = 1.2 mL/min, UV detection at 238 nm];  $t_{\text{R}}$  major 48 min (97%); and  $t_{\text{R}}$  minor 49.4 min (3%).


Hydrogenation of **9** over Pd/C and tosylation of the resulting amine afforded the *N*-furfuryl-sulfonamide (*R*)-**10**. Finally, oxidative cyclization of compound **10** using a modified version of the standard aza-Achmatowich rearrangement conditions furnished the target dihydropyridone **5**.

**Scheme 1.** Synthesis of Key Intermediate Dihydropyridone **5**.




**Reagents and Conditions.** (a)  $\text{HgSO}_4$ ,  $\text{H}_2\text{SO}_4$ , MeOH; (b) TBDPSCl, imidazole, DMAP, DMF; (c) DEAD,  $\text{PPh}_3$ ,  $\text{PhCO}_2\text{H}$ , THF; (d) MeOH, aqueous NaOH; (e) DPPA, DBU, toluene, 0 °C; (f) 1.  $\text{H}_2$ , Pd/C, EtOAc; 2. TsCl,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ; (g) *m*-CPBA,  $\text{CH}_2\text{Cl}_2$ .

The diastereomeric purity of the product was revealed by  $^1\text{H}$ -NMR and HPLC, since the presence of the other diastereoisomer was not detected, while the stereochemistry of the newly formed stereocenter was determined by 2D-NOESY spectroscopic analysis (the absolute configuration at C-2 derives from the starting material). Thus, the clear strong cross peak observed between the protons on C-2 and C-6 is indicative of their *cis pseudo*-diaxial conformation (Figure 2). Furthermore, the observed NOE between the aromatic protons of the tosyl group and the protons of *tert*-butyldiphenylsilyloxymethyl group confirmed this configuration. Finally, the observed optical rotation value for this compound ( $[\alpha]_{\text{D}}^{22}$  –25.5) constitutes additional proof of the assigned configuration, since its enantiomer displays the opposite sign ( $[\alpha]_{\text{D}}^{22}$  +27.9) [20b].


**Figure 2.** NOE Correlations in **5**.

As depicted in Scheme 2, dihydropyridone **5** was treated with  $\text{HC}(\text{OMe})_3$  in the presence of  $\text{BF}_3 \cdot \text{OEt}_2$  to furnish acetal **11**, which under modified Luche reduction conditions ( $\text{NaBH}_4$ ,  $\text{CeCl}_3$ ) was converted to allylic alcohol **12**. Subsequent catalytic hydrogenation of alcohol **12** produced piperidinol **13**, whose configuration was elucidated by 2D-COSY and NOESY NMR studies. Thus, the NOE correlation between the  $\text{H-5}_{\text{ax}}$  and  $\text{H-3}_{\text{ax}}$  and the small coupling constant between the  $\beta$   $\text{H-2}$  and  $\text{H-3}$  are indicative of the  ${}^4\text{C}_1$  chair conformation and the  $\alpha$  equatorial disposition of the hydroxy group. This intermediate may be incorporated into the stereoselective synthesis of (+)-desoxoprosophylline (**1**), according to already published synthetic routes [1, 24].

Finally, oxidation of dihydropyridone **5** with Jones reagent produced in almost quantitative yield the corresponding  $\alpha,\beta$ -unsaturated- $\gamma$ -keto- $\delta$ -lactam **14** (Scheme 3). The latter was diastereoselectively reduced under modified Luche conditions ( $\text{NaBH}_4$  and  $\text{CeCl}_3$ ) to 5,6-dihydropyridin-2-one **15**. This product is the key substrate for the syntheses of deoxymannojirimycin (**3**) and D-mannolactam (**4**), according to a recently published synthetic pathway [25].

**Scheme 2.** Synthesis of (+)-Desoxoprosophylline (**1**).

*Reagents and Conditions.* (a)  $\text{HC}(\text{OMe})_3$ ,  $\text{BF}_3 \cdot \text{OEt}_2$ , 4Å molecular sieves, THF, 0 °C; (b)  $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ ,  $\text{NaBH}_4$ , MeOH; (c)  $\text{H}_2$ , Pd/C, MeOH.

**Scheme 3.** Synthesis of Deoxymannojirimycin (**3**) and D-Mannolactam (**4**).

*Reagents and conditions.* (a) Jones Reagent, acetone, -10 °C; (b) CeCl<sub>3</sub>·7H<sub>2</sub>O, NaBH<sub>4</sub>, MeOH.

## Conclusions

In summary, we have demonstrated a concise synthetic route to (2*R*)-hydroxymethyl-dihydropyridone **5**, a chiral key intermediate useful in the synthesis of a variety of naturally occurring bioactive piperidine alkaloids, such as (+)-desoxoprosopphylline, deoxymannojirimycin and D-mannolactam.

## Experimental

### General

Air- and /or moisture sensitive reactions were carried out under an argon atmosphere in flame-dried glassware. Solvents were distilled from the appropriate drying agents prior to use. All starting materials were purchased from Aldrich (analytical reagent grades) and used without further purification. 2-(tert-Butyldiphenylsilyloxy)-1-(2-furyl)ethanol (**6**,  $[\alpha]_D^{22} +28.7$ ,  $c$  2.03, MeOH) was prepared according to a literature procedure [22]. All reactions were monitored by thin-layer chromatography using TLC sheets coated with silica gel 60 F<sub>254</sub> (Merck); spots were visualized with UV light or/and an alcohol solution of anisaldehyde. Products were purified by flash chromatography on Merck silica gel 60 (230-400 mesh ASTM). Melting points (uncorrected): Büchi melting point apparatus. FT-IR: Nicolet Magna 750, series II. Samples were recorded as KBr pellets, unless otherwise stated. Optical rotations were measured with a Perkin-Elmer-241 polarimeter. <sup>1</sup>H-NMR spectra were recorded on a Bruker DRX-400 (400 MHz) spectrometer, in CDCl<sub>3</sub>. Chemical shifts are referenced to internal TMS. Coupling constants (*J*) are expressed in Hz. HPLC: Hewlett Packard 1100 series instrument with a variable wavelength UV detector and coupled to HP Chem-Station utilizing the manufacturer's 5.01 software package.

(*S*)-Ethyl-2-(*tert*-butyldiphenylsilyloxy)-1-furan-2-yl benzoate (**7**). Diethyl azodicarboxylate (DEAD) (0.91 g, 5.86 mmol) was added dropwise to a solution of (*R*)-2-(*tert*-butyldiphenylsilyloxy)-1-furan-2-yl-ethanol **6** (1.8 g, 4.91 mmol), PPh<sub>3</sub> (3.09 g, 11.76 mmol) and benzoic acid (1.44 g, 11.52 mmol) in dry THF (15 mL). After the mixture was stirred for 1.5 h, the solvent was evaporated. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and washed with sat. aq. NaHCO<sub>3</sub> (60 mL), H<sub>2</sub>O (80 mL) and brine. The organic phase was separated and dried over MgSO<sub>4</sub>, the solvent evaporated and the residue chromatographed (hexane/EtOAc 95:5, *R<sub>f</sub>* = 0.70) yielding 1.73 g (75%) of compound **7** as a colorless oil. [ $\alpha$ ]<sub>D</sub><sup>22</sup> −5.7 (c 1.00, EtOAc); <sup>1</sup>H-NMR  $\delta$ : 1.42 (s, 9H, C-CH<sub>3</sub>), 4.53 (dd, *J* = 10.7, 4.8, 1H, CH<sub>2</sub>), 4.65 (dd, *J* = 10.7, 4.8, 1H, CH<sub>2</sub>), 6.78 (dd, *J* = 7.2, 4.9, 1H, CH), 6.88 (d, *J* = 6.8, 1H, H-3), 7.70–8.10 (m, 15H, Ph-H, H-4, H-5), 8.50 (d, *J* = 6.8, 2H, Ph-H); Anal. Calcd. for C<sub>29</sub>H<sub>30</sub>O<sub>4</sub>Si (470.63) C, 74.01; H, 6.43. Found: C, 74.19; H, 6.30.

(*S*)-2-(*tert*-Butyldiphenylsilyloxy)-1-furan-2-yl-ethanol (**8**). Aqueous NaOH (10%, 0.5 mL) was added dropwise to a solution of compound **7** (1.2 g, 2.55 mmol) in MeOH (100 mL) and the reaction was run at r.t. for 3 h. The resulting mixture was quenched with sat. aq. NH<sub>4</sub>Cl (3 mL) and extracted with EtOAc (2×150 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Purification by flash chromatography (hexane/EtOAc 95:5, *R<sub>f</sub>* = 0.27) gave 0.75 g (80%) of the title compound **8** as a colorless oil. [ $\alpha$ ]<sub>D</sub><sup>22</sup> −4.2 (c 1.03, EtOAc); IR (neat):  $\tilde{\nu}$  = 3350 (OH), 740, 1020 (furan) cm<sup>−1</sup>; <sup>1</sup>H-NMR  $\delta$ : 1.07 (s, 9H, C-CH<sub>3</sub>), 3.95 (d, *J* = 1.4, 2H, CH<sub>2</sub>), 4.83 (m, 1H, CH), 6.27 (d, *J* = 3.2, 1H, H-3), 6.3 (dd, *J* = 5.0, 1.8, 1H, H-4), 7.3–7.6 (m, 11H, Ph-H, H-5); Anal. Calcd. for C<sub>22</sub>H<sub>26</sub>O<sub>3</sub>Si (366.53): C, 72.09; H, 7.15. Found: C, 72.31; H, 7.02.

(*R*)-(2-Azido-2-furan-2-yl-ethoxy)-*tert*-butyldiphenylsilane (**9**). To an ice-cold solution of (2*S*)-2-furyl glycol **8** (0.4 g, 1.09 mmol) and diphenylphosphoryl azide (0.23 mL, 1.09 mmol) in dry toluene (3 mL) was added DBU (0.16 mL, 1.09 mmol) in small portions and the resulting mixture stirred for 2 h at 0 °C. The mixture was allowed to reach the room temperature, stirred for an additional 20 h and then washed successively with H<sub>2</sub>O (2×3 mL) and 5% HCl (2 mL), dried over MgSO<sub>4</sub> and the organic layer concentrated under reduced pressure. Purification by silica gel chromatography (hexane/EtOAc 95:5, *R<sub>f</sub>* = 0.87) afforded 0.33 g (78%) of azide **9** as colorless oil. [ $\alpha$ ]<sub>D</sub><sup>22</sup> +50.8 (c 1.01, EtOAc); IR (neat):  $\tilde{\nu}$  = 2110 (N<sub>3</sub>), 742, 1020 (furan) cm<sup>−1</sup>; <sup>1</sup>H-NMR  $\delta$ : 1.10 (s, 9H, C-CH<sub>3</sub>), 4.01 (d, *J* = 6.7, 2H, CH<sub>2</sub>), 4.60 (t, *J* = 5.5, 1H, CH), 6.37 (d, *J* = 1.8, 2H, H-3, H-4), 7.45 (m, 7H, H-5, Ph-H), 7.70 (m, 4H, Ph-H); Anal. Calcd. for C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>Si (391.54): C, 67.49; H, 6.44; N, 10.73. Found: C, 67.27; H, 6.52; N, 10.59.

(*R*)-*N*-[2-(*tert*-Butyldiphenylsilyloxy)-1-furan-2-yl-ethyl]-4-methylbenzenesulfonamide (**10**). Azide **9** (0.4 g, 1.02 mmol) was dissolved in EtOAc (10 mL) and hydrogenated over 10% Pd/C (0.04 g) under 1 bar pressure for 40 min. The reaction mixture was filtered over Celite<sup>®</sup> and concentrated *in vacuo*. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and Et<sub>3</sub>N (0.2 mL, 1.5 mmol) was added. The resulting solution was cooled to 0 °C and p-TsCl (0.28 g, 1.5 mmol) was added portionwise under stirring. The reaction mixture was allowed to reach r.t., stirred for an additional 3 h. and then extracted successively with sat. aq. NaHCO<sub>3</sub> (2 mL) and brine, dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was chromatographed (hexane/EtOAc 4:1, *R<sub>f</sub>* = 0.4) yielding 0.5 g (94%) of the desired product **10** in pure crystalline form. M.p. 101–103 °C; [ $\alpha$ ]<sub>D</sub><sup>22</sup> +5.5 (c 1.01, EtOAc); IR (neat):  $\tilde{\nu}$  = 3285

(N-H), 740, 1030 (furan),  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$   $\delta$ : 0.99 (s, 9H, C-CH<sub>3</sub>), 2.41 (s, 3H, PhCH<sub>3</sub>), 3.72 (dd,  $J$  = 10.1, 4.9, 1H, CH<sub>2</sub>), 3.85 (dd,  $J$  = 10.1, 4.9, 1H, CH<sub>2</sub>), 4.43 (m, 1H, CH), 5.2 (d,  $J$  = 7.6, 1H, NH), 6.13 (d,  $J$  = 3.11, 1H, H-3), 6.24 (dd,  $J$  = 3.1, 1.9, 1H, H-4), 7.20–7.52 (m, 13H, Ph-H, H-5), 7.22 (d,  $J$  = 8.3, 1H), 7.66 (d,  $J$  = 8.0, 2H, Ph-H); Anal. Calcd. for C<sub>29</sub>H<sub>33</sub>NO<sub>4</sub>SSi (519.73): C, 67.02; H, 6.40; N, 2.70. Found: C, 66.78; H, 6.30; N, 2.81.

(2*R*,6*S*)-2-(*tert*-Butyldiphenylsilyloxyphenyl)-6-hydroxy-1-(toluene-4-sulfonyl)-1,6-dihydropyridin-3-(2*H*)-one (**5**). To a stirred solution of *N*-tosylfurfurylamine **10** (0.1 g, 0.19 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (1 mL), *m*-chloroperbenzoic acid (70%, 0.08 g, 0.33 mmol) was added in small portions. The reaction was run at r.t. for 4 h, then washed successively with 20% aq KI (1 mL), 30% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2 mL), sat. aq. NaHCO<sub>3</sub> (2 mL), H<sub>2</sub>O (3 mL) and brine. Concentration under reduced pressure gave a yellowish solid, which was purified by flash chromatography (hexane/EtOAc 4:1,  $R_f$  = 0.28) providing 0.09 g (88%) of the title compound **5** as a pale white solid. A small sample was crystallized from an Et<sub>2</sub>O/hexane mixture as off white needles. M.p. 97–99 °C;  $[\alpha]_D^{25}$  –25.5 (c 1.00, MeOH); IR (neat):  $\tilde{\nu}$  = 3397 (OH), 1692 (C=O), 1595 (C=C)  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$   $\delta$ : 0.95 (s, 9H, C-CH<sub>3</sub>), 2.45 (s, 3H, PhCH<sub>3</sub>), 3.60 (dd,  $J$  = 10.7, 2.4, 1H, CH<sub>2</sub>), 3.90 (dd,  $J$  = 10.7, 2.4, 1H, CH<sub>2</sub>), 4.55 (m, 1H, H-2), 4.96 (d,  $J$  = 11.5, 1H, OH), 6.10 (m, 1H, H-6), 6.22 (d,  $J$  = 10.4, 1H, H-4), 7.08 (dd,  $J$  = 10.4, 4.8, 1H, H-5), 7.3–7.5 (m, 12H, Ph-H), 7.79 (d,  $J$  = 8.0, 2H, Ph-H); Anal. Calcd. for C<sub>29</sub>H<sub>33</sub>NO<sub>5</sub>SSi (535.73): C, 65.02; H, 6.21; N, 2.61. Found: C, 65.17; H, 6.28; N, 2.68.

(2*R*,6*S*)-2-(*tert*-Butyldiphenylsilyloxyphenyl)-6-methoxy-1-(toluene-4-sulfonyl)-1,6-dihydropyridin-3-(2*H*)-one (**11**). BF<sub>3</sub>·Et<sub>2</sub>O (0.23 mL) was added to an ice-cold solution of pyridone **5** (0.5 g, 0.93 mmol), trimethyl orthoformate (0.3 mL, 2.75 mmol) and 4Å molecular sieves (0.35 g) in dry THF (7 mL). The reaction mixture was stirred for 3 h at 0 °C, quenched with H<sub>2</sub>O (5 mL) and extracted with Et<sub>2</sub>O (2×10 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub> and concentrated under reduced pressure to give a yellowish solid which was chromatographed (hexane/EtOAc 4:1,  $R_f$  = 0.32) to furnish 0.45 g (88%) of desired product **11** as colorless fine needles. M.p. 84–86 °C;  $[\alpha]_D^{25}$  –45 (c 1.02, EtOAc); IR (neat):  $\tilde{\nu}$  = 1694 (C=O), 1596 (C=C)  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$   $\delta$ : 1.07 (s, 9H, C-CH<sub>3</sub>), 2.39 (s, 3H, PhCH<sub>3</sub>), 3.54 (s, 3H, CH<sub>3</sub>), 3.97 (dd,  $J$  = 10.2, 6.6, 1H, CH<sub>2</sub>), 4.07 (dd,  $J$  = 10.2, 6.6, 1H, CH<sub>2</sub>), 4.47 (t,  $J$  = 6.9, 1H, H-2), 5.51 (d,  $J$  = 4.3, 1H, H-6), 5.74 (d,  $J$  = 10.36, 1H, H-4), 6.68 (dd,  $J$  = 10.3, 4.4, 1H, H-5), 7.24 (d,  $J$  = 7.4, 2H, Ph-H), 7.44 (m, 6H, Ph-H), 7.55 (d,  $J$  = 8.2, 2H, Ph-H), 7.67 d,  $J$  = 7.4, 4H, Ph-H); Anal. Calcd. for C<sub>30</sub>H<sub>35</sub>NO<sub>5</sub>SSi (549.75): C, 65.54; H, 6.42; N, 2.55. Found: C, 65.69; H, 6.52; N, 2.44.

(2*R*,3*S*,6*S*)-2-(*tert*-Butyldiphenylsilyloxymethyl)-6-methoxy-1-(toluene-4-sulfonyl)-1,2,3,6-tetrahydropyridin-3-ol (**12**). NaBH<sub>4</sub> (23.5 mg, 0.62 mmol) was added portionwise to a stirred solution of compound **11** (0.1 g, 0.18 mmol) and CeCl<sub>3</sub>·7H<sub>2</sub>O (33.1 mg, 0.09 mmol) in MeOH (2 mL) at –30 °C. After 40 min of stirring at that temperature, the reaction was quenched with sat. aq. NaHCO<sub>3</sub> (2 mL) and extracted with Et<sub>2</sub>O (2×10 mL). The combined organic phases were washed with brine, dried (MgSO<sub>4</sub>) and chromatographed (hexane/EtOAc 4:1,  $R_f$  = 0.3) to afford 90 mg (88%) of **12** as a colorless oil, which crystallized in Et<sub>2</sub>O/hexane as colorless fine needles. M.p. 106–107 °C;  $[\alpha]_D^{25}$  –32.5 (c 0.98, EtOAc); IR (neat):  $\tilde{\nu}$  = 3460 (OH), 1650 (C=C)  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$   $\delta$ : 1.05 (s, 9H, C-CH<sub>3</sub>), 2.42 (s,

3H, PhCH<sub>3</sub>), 3.31 (s, 3H, CH<sub>3</sub>), 3.77 (dd,  $J = 10.6, 4.2$ , 1H, CH<sub>2</sub>), 3.95 (m, 1H, H-3), 4.17 (d,  $J = 6.85$ , 1H, OH), 4.2 (m, 1H, H-2), 4.4 (t,  $J = 10.3$ , 1H, CH<sub>2</sub>), 5.24 (m, 1H, H-6), 5.69 (m, 1H, H-5), 5.84 (m, 1H, H-4), 7.25 (t,  $J = 9.01$ , 2H, Ph-H), 7.4-7.5 (m, 6H, Ph-H), 7.6-7.7 (m, 6H, Ph-H); Anal. Calcd. for C<sub>30</sub>H<sub>37</sub>NO<sub>5</sub>SSi (551.8): C, 65.30; H, 6.76; N, 2.54. Found: C, 65.55; H, 6.90; N, 2.63.

*2-(tert-Butyldiphenylsilyloxymethyl)-6-methoxy-1-(toluene-4-sulfonyl)-piperidin-3-ol (13)*. Allylic alcohol **12** (0.52 g, 1 mmol) was dissolved in MeOH (15 mL) and hydrogenated over 10% Pd/C (52 mg) under 1 bar pressure for 2 h. The mixture was filtered over Celite<sup>®</sup>, evaporated and partitioned between EtOAc and water. The aqueous layer was backwashed with EtOAc. The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub> and concentrated. The yellowish slurry was chromatographed (hexane/EtOAc 4:1,  $R_f = 0.29$ ) to give 90 mg (90%) of compound **13** as an off-white solid. M.p. 98-100 °C;  $[\alpha]_D^{25} -15.5$  (c 1.02, EtOAc); IR (neat):  $\tilde{\nu} = 3500$  (OH) cm<sup>-1</sup>; <sup>1</sup>H-NMR  $\delta$ : 1.07 (s, 9H, C-CH<sub>3</sub>), 1.65 (m, 2H, H-4), 1.9 (m, 2H, H-5), 2.4 (s, 3H, PhCH<sub>3</sub>), 3.1 (s, 3H, CH<sub>3</sub>), 3.44 (m, 1H, H-3), 3.66 (m, 1H, CH<sub>2</sub>), 3.88 (dd,  $J = 10.2, 4.1$ , 1H, H-2), 4.35 (d,  $J = 6.26$ , 1H, OH), 4.5 (t,  $J = 10.4$ , 1H, CH<sub>2</sub>), 5.01 (m, 1H, H-6), 7.27 (t,  $J = 8.15$ , 2H, Ph-H), 7.3-7.5 (m, 6H, Ph-H), 7.6-7.7 (m, 6H, Ph-H); Anal. Calcd. for C<sub>30</sub>H<sub>39</sub>NO<sub>5</sub>SSi (553.8): C, 65.07; H, 7.10; N, 2.53. Found: C, 65.31; H, 7.23; N, 2.42.

*(6R)-6-(tert-Butyldiphenylsilyloxymethyl)-6-methoxy-1-(toluene-4-sulfonyl)-1,6-dihydropyridine-2,5-dione (14)*. To an ice cold solution of compound **5** (0.1 g, 0.188 mmol) in acetone (1.3 mL) at -10 °C, was added dropwise Jones reagent (0.1 mL). After being stirred for 20 min, the solid inorganic by products were eliminated by decantation and the liquid layer was concentrated to a residue that was partitioned in EtOAc (4 mL) and H<sub>2</sub>O (2 mL). The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and evaporated. The residue was crystallized from cold Et<sub>2</sub>O/hexane to afford 95 mg (95%) of compound **14** as an off-white solid. M.p. 196-198 °C;  $R_f = 0.31$  (hexane/EtOAc 1:4);  $[\alpha]_D^{25} -10.7$  (c 1.00, EtOAc); IR (neat):  $\tilde{\nu} = 1725$  (C=O), 1692 (N-C=O) cm<sup>-1</sup>; <sup>1</sup>H-NMR  $\delta$ : 0.92 (s, 9H, C-CH<sub>3</sub>), 2.44 (s, 3H, PhCH<sub>3</sub>), 4.11 (dd,  $J = 10.6, 1.6$ , 1H, CH<sub>2</sub>), 4.42 (dd,  $J = 10.6, 1.6$ , 1H, CH<sub>2</sub>), 5.02 (s, 1H, H-6), 6.72 (d,  $J = 10.1$ , 1H, H-3), 6.8 (d,  $J = 10.1$ , 1H, H-4), 7.27 (d,  $J = 8.1$ , 2H, Ph-H), 7.3-7.55 (m, 10H, Ph-H), 7.94 (d,  $J = 8.3$ , 2H, Ph-H); Anal. Calcd. for C<sub>29</sub>H<sub>31</sub>NO<sub>5</sub>SSi (533.7): C, 65.26; H, 5.85; N, 2.62. Found: C, 65.01; H, 5.98; N, 2.49.

*(5S,6R)-2-(tert-Butyldiphenylsilyloxymethyl)-5-hydroxy-1-(toluene-4-sulfonyl)-5,6-dihydropyridin-2-one (15)*. NaBH<sub>4</sub> (24 mg, 0.64 mmol) was added portionwise to a stirred solution of compound **14** (0.1 g, 0.187 mmol) and CeCl<sub>3</sub>·7H<sub>2</sub>O (34 mg, 0.092 mmol) in MeOH (2 mL) at -30 °C. After 40 min of stirring at that temperature, the reaction was quenched with sat. aq. NaHCO<sub>3</sub> (2 mL) and extracted with Et<sub>2</sub>O (2×10 mL). The combined organic phases were washed with brine, dried (MgSO<sub>4</sub>) and chromatographed (hexane/EtOAc 4:1,  $R_f = 0.4$ ) to afford compound **15** (80 mg, 80%) as a pale white solid. M.p. 150-152 °C;  $[\alpha]_D^{25} -2.7$  (c 1.02, EtOAc); IR (neat):  $\tilde{\nu} = 1450$  (C=O), 1670 (N-C=O) cm<sup>-1</sup>; <sup>1</sup>H-NMR  $\delta$ : 0.92 (s, 9H, C-CH<sub>3</sub>), 2.44 (s, 3H, PhCH<sub>3</sub>), 3.82 (dd,  $J = 10.6, 4.2$ , 1H, CH<sub>2</sub>), 4.02 (dd,  $J = 10.6, 4.2$ , 1H, CH<sub>2</sub>), 4.17 (d,  $J = 6.85$ , 1H, OH), 5.04 (m, 1H, H-5), 5.04 (m, 1H, H-5), 5.07 (m, 1H, H-6), 5.60 (dd,  $J = 10.0, 4.2$ , 1H, H-4), 7.01 (dt,  $J = 10.2, 1.7$ , 1H, H-3), 7.2 (d,  $J = 7.2$ , 2H, Ph-H), 7.40-



7.52 (m, 6H, Ph-H), 7.60 (dd,  $J = 7.5, 1.5$ , 2H, Ph-H), 7.7 (d,  $J = 8.4$ , 4H, Ph-H); Anal. Calcd. for  $C_{29}H_{31}NO_5Si$  (533.7): C, 65.26; H, 5.85; N, 2.62. Found: C, 65.09; H, 5.71; N, 2.72.

## References

1. (a) Dransfield, J. R.; Gore, P. M.; Shipman, M.; Slawin A. M. Z. Divergent approach to imino sugar C-glycosides using imino glycals: application to the stereocontrolled synthesis of (+)-deoxoprosopphylline. *Chem. Commun.* **2002**, 2, 150-151; (b) Yang, C.-F.; Xu, Y.-M.; Liao, L.-X.; Zhou, W.-S. Asymmetric total synthesis of (+)-desoxoprosopphylline. *Tetrahedron Lett.* **1998**, 39, 9227-9228.
2. Schneider, M. J. *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Pergamon: Oxford, **1996**; Vol. 10, pp. 155-299.
3. Stutz, A. E. *Iminosugars as Glycosidase Inhibitors*; Wiley-VCH: Weinheim, **1998**.
4. Hughes, A. B.; Rudge, A. J. Deoxynojirimycin – synthesis and biological activity. *Nat. Prod. Rep.* **1994**, 11, 135-162.
5. (a) Butters, T. D.; Dwek, R. A.; Platt, F. M. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. *Glycobiology*, **2005**, 10, R-43-R52; (b) Butters, T. D.; Dwek, R. A.; Platt, F. M. Therapeutic applications of imino sugars in lysosomal storage disorders. *Curr. Top. Med. Chem.* **2003**, 3, 561-574.
6. Ye, X.-S.; Sun, F.; Liu, M.; Li, Q.; Wang, Y.; Zhang, G.; Zhang, L.-H.; Zhang, X.-L. Synthetic iminosugar derivatives as new potential immunosuppressive agents. *J. Med. Chem.* **2005**, 48, 3688-3691.
7. (a) Greimel, P.; Spreitz, J.; Stütz, A. E.; Wrodnigg, T. M. Iminosugars and relatives as antiviral and potential anti-infective agents. *Curr. Topics Med. Chem.* **2003**, 3, 513-523; (b) Robina, I.; Moreno-Vargas, A. J.; Carmona, A. T.; Vogel, P. Glycosidase inhibitors as potential HIV entry inhibitors?. *Curr. Drug. Metab.* **2004**, 5, 329-361.
8. Somsak, L.; Nagy, V.; Hadazy, Z.; Dosca, T.; Gergely, P. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: Recent developments. *Curr. Pharm. Design* **2003**, 9, 1177-1189.
9. (a) Lu, Y.; Xu, Y.-Y.; Fan, K.-Y.; Shen, Z.-H. 1-deoxymannojirimycin, the alpha 1,2-mannosidase inhibitor, induced cellular endoplasmic reticulum stress in human hepatocarcinoma cell 7721. *Biochem. Biophys. Res. Commun.* **2006**, 344, 221-225; (b) Martin, O. R.; Compain, P. Iminosugars: Recent insights into their bioactivity and potential as therapeutic agents – Preface. *Curr. Topics Med. Chem.* **2003**, 3, U2-U5;
10. Fuhrmann, U.; Bause, E.; Legler, G.; Ploegh, H. Novel Mannosidase Inhibitor Blocking Conversion of High Mannose to Complex Oligosaccharides. *Nature* **1984**, 307, 755-758.
11. Kato, A.; Kato, N.; Kano, E.; Adachi, I.; Ikeda, K.; Yu, L.; Okamoto, T.; Banba, Y.; Ouchi, H.; Takahata, H.; Asano, N. Biological properties of D- and L-1-deoxyazasugars. *J. Med. Chem.* **2005**, 48, 2036-2044.
12. Spreitz, J.; Stütz, A. E. Golgi endomannosidase inhibitor, alpha-D-glucopyranosyl-(1->3)-1-deoxymannojirimycin: a five-step synthesis from maltulose and examples of N-modified derivatives. *Carbohydr. Res.* **2004**, 339, 1823-1827.

13. Boucheron, C.; Compain, P.; Martin, O. R. A stereodivergent approach to 1-deoxynojirimycin, 1-deoxygalactonojirimycin and 1-deoxymannojirimycin derivatives. *Tetrahedron Lett.* **2006**, *47*, 3081-3084.
14. Kennedy, A.; Nelson, A.; Perry, A. Methods for the synthesis of polyhydroxylated piperidine by diastereoselective dihydroxylation. Exploitation in the two-directional synthesis of aza-C-linked disaccharide derivatives. *Beilstein J. Org. Chem.* **2005**, *1*:2; doi:10.1186/1860-5397-1-2.
15. Singh, O. V.; Han, H. A general methodology for the asymmetric synthesis of 1-deoxy-aminosugars. *Tetrahedron Lett.* **2003**, *44*, 2387-2391.
16. Boglio, C.; Stahlke, S.; Thorimbert, S.; Malacria, M. A stereoselective route toward polyhydroxylated piperidines. A total synthesis of (+/-)-deoxymannojirimycin. *Org. Lett.* **2005**, *7*, 4851-4854.
17. Pyun, S.-J.; Lee, K.-Y.; Oh, C.-Y.; Joo, J.-E.; Cheon, S.-H.; Ham, W.-H. Total synthesis of 1-deoxygulonojirimycin. Revision of the absolute configuration of the natural product. *Tetrahedron* **2005**, *61*, 1413-1416.
18. Takahata, H.; Banba, Y.; Sasatani, M.; Nemoto, H.; Kato, A.; Adachi, I. Asymmetric synthesis of 1-deoxynojirimycin and its congeners from a common chiral building block. *Tetrahedron* **2004**, *60*, 8199-8205.
19. Kirihara, M.; Nishio, T.; Yokohama, S.; Kakuda, H.; Momose, T. Hypervalent lambda(n)-iodane-mediated fragmentation of tertiary cyclopropanol systems - II: Application to asymmetric syntheses of piperidine and indolizidine alkaloids. *Tetrahedron* **1999**, *55*, 2911-2926.
20. (a) Zhou, W. S.; Lu, Z. H.; Wang, Z. M. An efficient preparation of optically-active alpha-furfuryl amide by kinetic resolution using the modified sharpless asymmetric epoxidation reagents. *Tetrahedron* **1993**, *49*, 2641-2654; (b) Koulocheri, S. D.; Magiatis, P.; Skaltsounis, A.-L.; Haroutounian, S. A. Stereoselective Michael addition of thiophenols, amino acids and hydrazoic acid to (2S)-hydroxymethyl-dihydropyridone as a convenient route to novel azasugar derivatives. *Tetrahedron* **2000**, *56*, 6135-6141.
21. Koulocheri, S. D.; Haroutounian, S. A. Transformation of D-glucal to (2S)-hydroxymethyl-dihydropyridones as intermediates to piperidine alkaloids. *Synthesis* **1999**, *11*, 1889-1892.
22. Hauser, F. M.; Ellenberger, S. R.; Ellenberger, W. P. A simple procedure for the preparation of L-hexoses. *Tetrahedron Lett.* **1988**, *29*, 4939-4942.
23. Thompson, A. S.; Humphrey, G. R.; De Marco, A. M.; Mathre, D. J.; Grabowski, E. J. J. Direct conversion of activated alcohols to azides using diphenyl phosphorazidate – A practical alternative to Mitsunobu conditions. *J. Org. Chem.* **1993**, *58*, 5886-5888.
24. Yang, C.; Liao, L.; Xu, Y.; Zhang, H.; Xia, P.; Zhou, W. New concise asymmetric total synthesis of (+)-desoxoprosopphylline and prosopphylline. *Tetrahedron: Asymmetry* **1999**, *10*, 2311-2318.
25. Knight, J. G.; Tchabanenko, K. Total synthesis of deoxymannojirimycin and D-mannolactam via carbonylation of 5-vinyloxazolidin-2-ones. *Tetrahedron* **2003**, *59*, 281-286.

*Sample availability:* Available from the authors.